Physician profile
Robert B Smith
NPI 1033167002
$592.40
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $592.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $143.26 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $130.35 | 2019 | |
| Pfizer INC. | $123.02 | 2019 | |
| Boston Scientific Corporation | $33.44 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $28.50 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.25 | 2019 | |
| Astellas Pharma US INC | $18.10 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.09 | 2019 | |
| Amarin Pharma, INC. | $16.99 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.71 | 2019 | |
| Amgen INC. | $16.23 | 2019 | |
| Hikma Pharmaceuticals USA | $15.54 | 2019 | |
| Sanofi Pasteur INC. | $11.92 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.